Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial tags : Fda save search
Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia
Published: 2024-04-15 (Crawled : 13:00) - globenewswire.com
RVPH | $3.09 2.32% 2.27% 110K
|
|
| O: -7.05%
H: 4.96%
C: 1.46%
fda brilaroxazine trials for schizophrenia
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
Published: 2024-04-15 (Crawled : 13:00) - globenewswire.com
RNAZ | $0.4546 -6.27% -6.69% 280K
|
Professional, Scientific, and T...
|
| O: 0.11%
H: 5.95%
C: -13.78%
mc138 fda ttx-mc138 tumors clearance trial therapeutics advanced
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
Published: 2024-04-11 (Crawled : 12:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 1.85%
H: 0.0%
C: 0.0%
biotech fda breast cancer for meeting trial submission
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
Published: 2024-04-09 (Crawled : 10:00) - prnewswire.com
BCLI A | $0.548 3.01% 2.92% 360K
|
Health Technology
|
| O: 10.45%
H: 0.0%
C: 0.0%
fda als cell for trial therapeutics agreement
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication
Published: 2024-04-08 (Crawled : 11:00) - globenewswire.com
OCGN | News A | $1.23 -6.82% -7.32% 7.6M
|
Health Technology
|
| O: 26.42%
H: 3.48%
C: -6.47%
ocu400 fda first clearance trial therapy
iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency in the U.S.
Published: 2024-04-04 (Crawled : 23:00) - biospace.com/
DTIL | $9.85 1.13% 1.12% 47K
|
Health Technology
|
| O: -2.33%
H: 1.64%
C: -4.91%
ecur-506 fda drug treatment clearance for application trial
Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
Published: 2024-04-03 (Crawled : 12:00) - biospace.com/
CANF | $1.91 -3.54% 3.67% 8.7K
|
Health Technology
|
| O: 2.45%
H: 0.87%
C: -0.43%
fda namodenoson application trial
SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCC
Published: 2024-03-27 (Crawled : 23:00) - biospace.com/
REGN | News | $899.71 0.32% 0.32% 340K
|
Health Technology
|
| O: 0.78%
H: 0.4%
C: -0.49%
ren026 fda study
FDA Rejects Regeneron’s Blood Cancer Therapy for Two Forms of Lymphoma
Published: 2024-03-25 (Crawled : 16:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -100.0%
H: NaN%
C: Infinity%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 0.42%
H: 0.0%
C: 0.0%
fda cancer blood therapy
Evie Ring's Pulse Oximeter Exceeds FDA Accuracy Guidelines in Movano Health's Second Hypoxia Trial
Published: 2024-03-14 (Crawled : 23:00) - prnewswire.com
MOVE | $0.461 -6.38% -6.81% 70K
|
Manufacturing
|
| O: 0.24%
H: 0.0%
C: -12.74%
guidelines fda trial
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
Published: 2024-03-14 (Crawled : 12:30) - biospace.com/
CYBN | $0.3604 -1.99% -0.11% 2.3M
|
n/a
|
| O: 7.14%
H: 5.53%
C: -4.67%
cyb003 fda positive meeting program design
60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024
Published: 2024-03-14 (Crawled : 12:00) - globenewswire.com
SXTP | $0.246 2.08% 2.03% 150K
|
n/a
|
| O: -0.34%
H: 4.59%
C: -6.99%
fda pharmaceuticals communication trial submission
Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial
Published: 2024-03-11 (Crawled : 11:00) - globenewswire.com
NRIX 6 d | $13.58 -0.07% -0.07% 570K
|
Health Technology
|
| O: 1.14%
H: 4.19%
C: -5.93%
nx-2127 fda trial therapeutics
Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer
Published: 2024-03-04 (Crawled : 12:00) - globenewswire.com
IOVA M | $11.33 0.18% 0.18% 2.4M
|
Health Technology
|
| O: 7.77%
H: 0.8%
C: -6.27%
lun-202 fda lung lifted cancer cell trial
BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS
Published: 2024-02-23 (Crawled : 11:00) - prnewswire.com
BCLI A | $0.548 3.01% 2.92% 360K
|
Health Technology
|
| O: 8.93%
H: 6.33%
C: -3.06%
nurown fda als cell trial therapeutics
Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
Published: 2024-02-20 (Crawled : 12:30) - globenewswire.com
MTNB | $0.18 -4.1% 0.44% 1.4M
|
Health Technology
|
| O: 4.35%
H: 11.21%
C: -0.46%
mat2203 fda treatment biopharma trial agreement
Tonix Pharmaceuticals Hosted KOL Webinar on Positive Phase 3 Fibromyalgia Trial for Tonmya™, Plans to File NDA for FDA Approval in Second Half of 2024
Published: 2024-02-14 (Crawled : 13:00) - globenewswire.com
TNXP | $0.1579 -1.31% -1.33% 1.4M
|
Health Technology
|
| O: 5.61%
H: 3.54%
C: 3.54%
fda fibromyalgia approval positive pharmaceuticals trial
Tonix Pharmaceuticals Announces FDA IND Clearance for DoD Funded Trial of TNX-102 SL for the Reduction of Acute Stress Reaction and Prevention of PTSD
Published: 2024-02-12 (Crawled : 13:00) - globenewswire.com
TNXP | $0.1579 -1.31% -1.33% 1.4M
|
Health Technology
|
| O: 4.55%
H: 11.71%
C: 7.25%
tnx-102 fda clearance pharmaceuticals trial
Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs
Published: 2024-02-06 (Crawled : 14:00) - globenewswire.com
VERU | $1.27 -3.05% -3.15% 1.4M
|
Health Technology
|
| O: -1.04%
H: 1.51%
C: -9.12%
fda treat clearance application trial
Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms
Published: 2024-02-05 (Crawled : 15:00) - biospace.com/
AIMD | $1.02 -0.97% -0.98% 12K
|
Manufacturing
|
| O: 11.65%
H: 0.0%
C: -6.09%
covid-19 fda drug resolve trial response
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.